The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study)
Open accessAbstract
Aim: To investigate the effects of switching from liraglutide or dulaglutide to once‐weekly semaglutide on glycaemic control and treatment satisfaction in patients with type 2 diabetes. Materials and Methods: In this multicentre, open‐labelled, prospective, randomized, parallel‐group comparison study, patients treated with liraglutide 0.9‐1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy. The primary endpoint was the mean change in glycated haemoglobin over 24 weeks. The secondary endpoints included the changes of Diabetes Treatment Satisfaction Questionnaire scores, body weight and metabolic indices. Results: In total, 110 patients were enrolled, and 10 were excluded; therefore, 37 patients in plan A and 63 patients in plan B completed the study. Glycated haemoglobin levels were significantly reduced in the semaglutide group in both plans [plan A, 7.8% ± 1.0% to 7.8% ± 0.7% (liraglutide) vs. 7.9% ± 0.7% to 7.3% ± 0.7% (semaglutide), p < .01; plan B, 7.8% ± 1.0% to 7.9% ± 1.2% (dulaglutide) vs. 7.8% ± 0.8% to 7.1% ± 0.6% (semaglutide), p < .01]. Semaglutide also improved Diabetes Treatment Satisfaction Questionnaire scores in both groups (plan A, +0.1 vs. +8.3, p < .01; plan B, −1.2 vs. +3.5, p < .01). Switching from dulaglutide yielded greater reductions in body weight and improved metabolic parameters. Conclusions: Once‐weekly semaglutide administration improved glycaemic control and treatment satisfaction after switching from liraglutide or dulaglutide. These results highlighted a useful treatment option for patients with metabolic abnormalities despite glucagon‐like receptor‐1 receptor agonist treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The treatment response observed in our analysis may be influenced by ethnic differences, given that five RCTs recruited exclusively Japanese participants.
“the treatment response observed in our analysis may also be influenced by ethnic differences, given that five RCTs recruited exclusively Japanese participants [39–41, 48, 49]”
Most trials were multinational, except for five that recruited exclusively Japanese participants.
“Most trials were multinational, except for five that recruited exclusively Japanese participants [39–41, 48, 49].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Recent clinical trials illustrated that these drugs have beneficial effects on cardiovascular and renal outcomes.(10,11) Owing to these benefits, treatment strategies featuring GLP-1RAs are important approaches for select patients.”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 1×
“Among them, the effects on body weight control via inhibiting gastric peristalsis and reducing appetite are important components of these drugs.(8,9) Recent clinical trials illustrated that these drugs have beneficial effects on cardiovascular and renal outcomes.”
BackgroundNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015) · Diabetes Care · doi:10.2337/dc14-0920 · Cited by 356
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Skov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128
Flagged first, then by citations
Research works printed but not linked: 16
- 10.2337/diacare.29.01.06.dc05-1341 · DOI
- 10.1016/S2213-8587(17)30327-3 · DOI · Paper page
- 10.1016/j.numecd.2019.04.009 · DOI · Paper page
- 10.1111/dom.12591 · DOI · Paper page
- 10.1016/S2213-8587(18)30104-9 · DOI · Paper page
- 10.1007/s13300-020-00986-9 · DOI
- 10.1111/jdi.12913 · DOI
- 10.1111/dom.12602 · DOI
- 10.1007/s13300-018-0397-1 · DOI
- 10.1016/j.diabet.2019.101117 · DOI · Paper page
- 10.1016/S2213-8587(18)30024-X · DOI · Paper page
- 10.1111/dom.13128 · DOI
- 10.1111/dom.12932 · DOI · Paper page
- 10.14814/phy2.13503 · DOI
- 10.1111/jdi.12906 · DOI
- 10.1007/s13300-018-0414-4 · DOI
Cited by
Sorted by citations
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06144-1 · Cited by 102
Metadata
- Authors
- Takahashi, Y., Nomoto, H., Yokoyama, H., Takano, Y., Nagai, S., Tsuzuki, A., Cho, K. Y., Miya, A., Kameda, H., Takeuchi, J., Taneda, S., Kurihara, Y., Atsumi, T., Nakamura, A., Miyoshi, H., & SWITCH‐SEMA 1 study group
- Affiliations
- Hokkaido University (JP)
- Jiyugaoka Medical Clinic Obihiro Japan
- Tonan Hospital (JP)
- NTT Medical Center Sapporo (JP)
- Sapporo Diabetes and Thyroid Clinic Sapporo Japan
- Diabetes Center Manda Memorial Hospital Sapporo Japan
- Kurihara Clinic Sapporo Japan
- Corresponding author
- Nomoto, Hiroshi
- Miyoshi, Hideaki
- ORCID
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-02-28
- Volume
- 25
- Issue
- 6
- Pages
- 1503-1511
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4318754266
- Cited by
- 29
- References
- 10
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 10 · 2023: 4
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, semaglutide, liraglutide, dulaglutide, GLP-1 receptor agonists, treatment switching, glycemic control, HbA1c, treatment satisfaction, body weight, metabolic parameters, insulin resistance, dyslipidemia
- MeSH terms
- Liraglutide, Glycemic Control, Semaglutide, Body Weight, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Personal Satisfaction, Prospective Studies, Recombinant Fusion Proteins, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
